Clinical trials: Rhinoconjunctivitis
Allergic Rhinitis, Allergic Rhinoconjunctivitis
MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)
The purpose of this study is to assess the effect on various biomarkers of treatment with MK-8237 in participants with allergic rhinitis or rhinoconjunctivitis.
- Trial name
- NCT01852825
- Testing
- MK-8237, NAC
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Rhinitis; Allergic, With Asthma, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00783198
- Testing
- SCH 39641 6 Amb a 1-U, SCH 39641 12 Amb a 1-U
- Volunteers
- 565 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Adolescent Mite Allergy Safety Evaluation
This is a 28-day clinical trial studying the safety of the house dust mite tablet in adolescents with allergic rhinitis/rhinoconjunctivitis.
- Trial name
- AMASE (NCT04541004)
- Testing
- HDM SLIT-tablet
- Where
- 27 sites in Czechia, Germany and 1 more
- Volunteers
- 253 people
- Sponsor
- ALK-Abelló A/S
Rhinitis, Allergic, Conjunctivitis
Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05234)
This study will evaluate the efficacy and safety of ragweed sublingual tablet (SCH 39641/MK-3641/Amb a 1-U) compared with placebo in participants with ragweed-induced rhinoconjunctivitis over a one-year period.
- Trial name
- NCT00770315
- Testing
- Ambrosia artemisiifolia allergen extract (Amb a 1-U)
- Volunteers
- 784 people
- Sponsor
- ALK-Abelló A/S
Allergy
Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy
The primary objective of this study is to demonstrate that SLIT administered pre-and co-seasonally is effective in reducing rhinoconjunctivitis symptoms during the entire short ragweed pollen season.
- Trial name
- NCT01353079
- Testing
- Short Ragweed Pollen Allergenic Extract
- Where
- United States
- Volunteers
- 429 people
- Sponsor
- Greer Laboratories
Seasonal Allergic Rhinitis, Rhinoconjunctivitis
Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen
The PQGrass306 (G306) clinical trial is the pivotal Phase III efficacy clinical trial of PQ Grass. The aim of the G306 pivotal clinical trial is to confirm the efficacy and safety of the optimal effective dose of PQ Grass 27600…
- Trial name
- NCT05540717
- Testing
- PQ Grass
- Where
- 102 sites in United States, Austria and 4 more
- Volunteers
- 555 people
- Sponsor
- Allergy Therapeutics
Rhinitis Allergic, Conjunctivitis
A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)
This is a study to evaluate the efficacy and safety of grass sublingual tablet (SCH 697243) versus placebo in the treatment of grass pollen-induced allergic hayfever symptoms.
- Trial name
- NCT01385371
- Testing
- Grass (Phleum pratense) pollen allergen extract
- Volunteers
- 1,501 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, Rhinoconjunctivitis
Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy
The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic rhinoconjunctivitis during the following birch pollen…
- Trial name
- NCT01720251
- Testing
- AllerT low dose, AllerT full dose
- Where
- 24 sites in Denmark, France and 5 more
- Volunteers
- 240 people
- Sponsor
- Anergis
Rhinoconjunctivitis, Rhinitis
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced…
- Conditions
- Rhinoconjunctivitis, Rhinitis, Conjunctivitis, Allergy
- Trial name
- NCT00978029
- Testing
- SCH 39641
- Volunteers
- 203 people
- Sponsor
- ALK-Abelló A/S
Allergy
Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever
The trial is performed to assess the efficacy and safety of SLIT One birch for treatment of birch pollen induced allergy
- Trial name
- NCT00310466
- Testing
- Sublingual immunotherapy
- Where
- Germany
- Volunteers
- 226 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus
House Dust Mite Allergy Trial In Children
A research study of how house dust mite tablets work compared to placebo in children aged between 5 and 11 years and who have allergy to house dust mites (MATIC)
- Conditions
- Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
- Trial name
- MATIC (NCT04145219)
- Testing
- Sublingual allergy immunotherapy tablet
- Where
- 113 sites in United States, Bulgaria and 9 more
- Volunteers
- 1,460 people
- Sponsor
- ALK-Abelló A/S
Rhinoconjunctivitis
Phase III Cat-PAD Study
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.
- Trial name
- NCT01620762
- Testing
- Cat-PAD
- Where
- 118 sites in United States, Belgium and 7 more
- Volunteers
- 1,408 people
- Sponsor
- Circassia Limited
Seasonal Allergic Rhinoconjunctivitis, Asthma
Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma
The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma
- Trial name
- SKY (NCT02761252)
- Testing
- Bilastine 20mg, Montelukast 10mg
- Where
- 32 sites in Croatia, Czechia and 6 more
- Volunteers
- 454 people
- Sponsor
- Menarini International Operations Luxembourg SA
Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis
Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study
TX-SMILE is an investigator-initiated, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intra-lymphatic administration of an approved…
- Conditions
- Allergic Rhinitis Due to Tree Pollen, Allergic Conjunctivitis, Allergic Rhinoconjunctivitis
- Trial name
- TX-SMILE (NCT03682965)
- Testing
- Intra-lymphatic allergenic extract
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Christopher Thompson, MD
Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal
Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.
- Trial name
- NCT01700192
- Testing
- MK-8237 tablets, Rescue Medication: Self-Injectable Epinephrine, Rescue Medication: Loratadine tablets
- Volunteers
- 1,482 people
- Sponsor
- ALK-Abelló A/S
Perennial Allergic Rhinoconjunctivitis, House Dust Mite Allergy
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of the combination treatment AllQbG10 in patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy in a double-blind, placebo-controlled setting
- Trial name
- NCT00574704
- Testing
- CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)
- Volunteers
- 40 people
- Sponsor
- Cytos Biotechnology AG
Rhinitis, Allergic, Seasonal
An Exploratory Study of PQ Grass 27600 SU
PQGrass309 is aimed at exploring the expected average treatment effect of PQ Grass 27600 SU cumulative dose on symptom and medication score in a field setting.
- Trial name
- NCT04687059
- Testing
- PQ Grass
- Where
- 14 sites in United States, Germany
- Volunteers
- 119 people
- Sponsor
- Allergy Therapeutics
Allergic Rhinoconjunctivitis
The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation
This pilot study is a Phase IV, single center, placebo-controlled, parallel study design conducted using the Environmental Exposure Unit (EEU).
- Trial name
- NCT02394600
- Testing
- Grastek®
- Where
- Canada
- Volunteers
- 93 people
- Sponsor
- Queen's University
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Efficacy and Safety of SUBLIVAC Phleum for Immunotherapy of Grass Pollen-Allergy
The purpose of this study is to assess safety, tolerability and demonstrate a dose response signal using Total Symptom Score (TSS), based on challenges with grass pollen in an Environmental Exposure Chamber (EEC), followed by…
- Trial name
- NCT02556801
- Testing
- SUBLIVAC FIX Phleum Prat.
- Where
- Canada
- Volunteers
- 168 people
- Sponsor
- HAL Allergy
Allergy
A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis
This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree…
- Trial name
- TreeTop (NCT04878354)
- Testing
- Tree SLIT-tablet
- Where
- 80 sites in Austria, Belgium and 9 more
- Volunteers
- 952 people
- Sponsor
- ALK-Abelló A/S